Geistlich Pharma

What Geistlich Pharma does

Geistlich Pharma AG is a Swiss family-owned medical device company founded in 1851 and headquartered in Wolhusen, Switzerland. It specializes in collagen-based regenerative biomaterials — primarily xenograft bone substitutes, collagen membranes, and porous collagen matrices — sold to dental, orthopedic, advanced wound care, and infectiology professionals through a global distribution network spanning more than 110 regions, with regional operating companies including Geistlich North America (Princeton, US). Its core product families include the Geistlich Bio-Oss bone substitute line, the Geistlich Bio-Gide membrane family (including Bio-Gide Forte launched in December 2025), Mucograft and Fibro-Gide matrices, the Yxoss CBR 3D titanium scaffold, the Chondro-Gide orthopedic cartilage regeneration system (including the AMIC technique variants), and the Derma-Gide advanced wound care collagen scaffold.

The company monetizes primarily through one-time sales of consumable medical devices to clinicians and institutions via local distributors, its own e-commerce storefronts, and direct field sales in selected markets. It does not publicly disclose pricing. Customer-facing value is built on a deep clinical evidence base (including the PIC Patient Outcome Registry), structured professional education through the Geistlich Education Hub, Regeneration Academy blog, Geistlich Magazine, webinars, and courses/congresses, and a multi-decade safety and efficacy track record across 'millions of treatments' worldwide. Geistlich positions itself as the No. 1 biomaterials brand in regenerative dentistry.

Geistlich has pursued an active inorganic strategy, completing acquisitions of Lynch Biologics in October 2022 to strengthen its US position and Bionnovation Biomedical in April 2024 to enter Latin America and emerging markets directly. In March 2025 it announced a strategic partnership with Stryker to co-develop next-generation collagen barrier membranes, and it has expanded its wound care partnership with StimLabs, yielding FDA 510(k) clearance for DermaForm in February 2026 and a planned Q2 2026 product launch. In March 2026, Geistlich divested its clinical-stage oncology program (misetionamide/GP-2250) to Persevere Therapeutics, narrowing focus back to regenerative biomaterials. The company is privately held with no disclosed funding rounds, parent company, or public shareholders, and reports a workforce of 501-1,000 employees.

Name

Geistlich Pharma

Legal name

Geistlich Pharma AG

Website

https://geistlich-pharma.com

Company type

Private

Founded year

1851

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Geistlich Pharma AG is a Swiss family-owned medical device company that develops and sells collagen-based regenerative biomaterials — bone substitutes, membranes, and matrices — to dental, orthopedic, wound care, and infectiology professionals across more than 110 regions worldwide.

Ownership category

akta.pro rank

Product category

Regenerative Medical Devices and Biomaterials

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112)

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG)

akta.pro secondary industries

Cartilage, Bone & Musculoskeletal Regeneration (HLAAAGAH), Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE), Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG)

Keywords

• Regenerative biomaterials
• Dental bone substitutes
• Collagen membranes
• Orthopedic cartilage regeneration
• Advanced wound care scaffolds

Headquarters

HQ city

Princeton

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales

Revenue model

1. Biomaterials and Medical Devices Sales: Geistlich generates revenue through the sale of regenerative biomaterials including bone substitutes, collagen membranes, and matrices to dental and orthopedic professionals. Products are sold through distributors, e-shops, and direct sales channels in over 110 regions globally.
2. Infectiology Products: Sale of infection control products including Geistlich TauroSept for disinfectiology applications.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Geistlich Pharma manufactures and sells collagen-based biomaterials and xenograft bone substitutes used in regenerative dental, orthopedic, wound care, and infectiology procedures. Its portfolio includes the Geistlich Bio-Oss family of bone substitutes, Geistlich Bio-Gide collagen membranes, Mucograft and Fibro-Gide matrices, Yxoss CBR 3-D titanium scaffolds, Chondro-Gide cartilage regeneration products, Geistlich Derma-Gide wound care scaffolds, and Geistlich TauroSept infection control products, distributed to clinical professionals globally.

Product overview

Geistlich Pharma is a global leader in regenerative biomaterials, offering a comprehensive portfolio of collagen-based products for dental, orthopedic, and wound care applications. The dental portfolio includes bone substitutes (Geistlich Bio-Oss family, Geistlich Combi-Kit, Geistlich Basis-Kit), collagen membranes (Geistlich Bio-Gide family including Bio-Gide, Bio-Gide Compressed, Bio-Gide Perio, Bio-Gide Shape, Bio-Gide Forte), matrices (Mucograft, Mucograft Seal, Fibro-Gide), 3D titanium scaffolds (Yxoss CBR), and instruments (Micross, Safescraper Twist). The orthopedic portfolio features bone regeneration products (Orthoss, Orthoss Collagen) and cartilage regeneration systems (Chondro-Gide, Jubilee Chondro-Gide, AMIC Knee/Talus/Hip/MTP, AMMR). Advanced wound care includes Geistlich Derma-Gide. The company also offers infectiology products (Geistlich TauroSept) and distributes partner products (OrthoPure XT, Lipogems). Products are available globally through e-shops in over 110 regions.

Differentiator

Problem solved

Functional benefit

Brands

• Geistlich Bio-Oss: Bone substitute product for dental applications
• Geistlich Bio-Oss Pen
• Geistlich Bio-Oss Collagen
• Geistlich Bio-Gide
• Geistlich Bio-Gide Forte
• Geistlich Bio-Gide Compressed
• Geistlich Bio-Gide Perio
• Geistlich Bio-Gide Shape
• Mucograft
• Mucograft Seal
• Fibro-Gide
• Yxoss CBR
• REGENFAST
• Pocket-X
• Allodyn
• Orthoss
• Orthoss Collagen
• Chondro-Gide
• Jubilee Chondro-Gide
• Geistlich TauroSept
• Derma-Gide
• Geistlich Combi-Kit
• Geistlich Basis-Kit

Products and services

• Geistlich Bio-Oss Xenograft bone substitute material derived from bovine bone, used for predictable bone and soft tissue regeneration in dental implantology and ridge preservation procedures. Targeted at dentists, periodontists, oral surgeons, and implantologists.
• Geistlich Bio-Oss Pen Bone substitute delivery system in a pen applicator format, designed for convenient application of Geistlich Bio-Oss during dental bone augmentation procedures.
• Geistlich Bio-Oss Collagen Collagen-enhanced bone substitute combining Geistlich Bio-Oss with collagen for improved handling, stability, and integration in dental bone regeneration procedures.
• Geistlich Combi-Kit Combination kit bundling a Geistlich bone substitute with a Geistlich collagen membrane for comprehensive dental bone and soft tissue regeneration procedures.
• Geistlich Basis-Kit Base kit providing foundational Geistlich biomaterials for dental bone augmentation procedures.
• Geistlich Bio-Gide Collagen membrane for guided tissue and bone regeneration (GTR/GBR) in dental procedures, used as a barrier membrane over bone grafts and for periodontal regeneration.
• Geistlich Bio-Gide Compressed Compressed variant of the Geistlich Bio-Gide collagen membrane for specialized dental bone and soft tissue regeneration applications.
• Geistlich Bio-Gide Perio Periodontal-specific collagen membrane variant of Geistlich Bio-Gide, designed for periodontal regeneration procedures.
• Geistlich Bio-Gide Shape Pre-shaped collagen membrane variant of Geistlich Bio-Gide, designed for specific dental bone and soft tissue regeneration procedures.
• Geistlich Bio-Gide Forte Enhanced collagen membrane with increased strength and improved handling properties for guided bone and soft tissue regeneration in dental implantology, designed to enhance implant survival rates.
• Mucograft Collagen matrix for soft-tissue regeneration, volume enhancement, and keratinized tissue gain in dental procedures.
• Mucograft Seal Collagen matrix variant designed specifically for sealing extraction sockets following tooth removal in dental procedures.
• Fibro-Gide Porcine-derived porous collagen matrix designed for soft-tissue augmentation and volume enhancement in dental procedures.
• Yxoss CBR Patient-specific 3-D titanium scaffold (Customized Bone Regeneration) for bone regeneration, customized bone augmentation, and complex alveolar ridge reconstruction in dental procedures.
• Geistlich Select REGENFAST Treatment solution system designed to accelerate bone regeneration in dental bone augmentation procedures.
• Pocket-X Gel Gel formulation indicated for the treatment of periodontal pockets as part of periodontal therapy.
• Allodyn Allograft Allograft tissue product for dental bone regeneration procedures, supplied through the Bionnovation Biomedical acquisition.
• Orthoss Bovine-derived bone substitute used for bone regeneration in orthopedic applications including spine, trauma, and reconstructive surgery.
• Orthoss Collagen Collagen-enhanced bovine bone substitute for orthopedic bone regeneration procedures.
• Chondro-Gide Collagen matrix used as a cover for cartilage defects in orthopedic cartilage repair using the Autologous Matrix-Induced Chondrogenesis (AMIC) technique.
• Jubilee Chondro-Gide Anniversary edition of the Chondro-Gide collagen matrix for cartilage repair procedures in orthopedics.
• AMIC Knee AMIC (Autologous Matrix-Induced Chondrogenesis) procedure kit/solution specifically configured for knee cartilage repair using Chondro-Gide.
• AMIC Talus AMIC (Autologous Matrix-Induced Chondrogenesis) procedure configured for repair of talus cartilage lesions using Chondro-Gide.
• AMIC Hip AMIC (Autologous Matrix-Induced Chondrogenesis) procedure configured for hip joint cartilage regeneration using Chondro-Gide.
• AMIC MTP AMIC (Autologous Matrix-Induced Chondrogenesis) procedure configured for metatarsophalangeal (MTP) joint cartilage repair using Chondro-Gide.
• AMMR Autologous Matrix-Induced Myocyte Regeneration (AMMR) system for muscle regeneration applications in orthopedics.
• Geistlich TauroSept

Quantifiable outcome

• Ridge preservation reduces residual ridge resorption with volume loss ranging from 3-18% depending on augmentation site

Named customers4 records

Segments6 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature9 records

Partnerships

Seven partnerships are on record, tiered minor and core.

• Persevere TherapeuticsminorOthers · 1 March 2026Persevere Therapeutics acquired the misetionamide (GP-2250) clinical-stage program and related assets from Geistlich Pharma AG. Geistlich divested this oncology program while Persevere advances the compound through Phase 1b/2a clinical trials for platinum-resistant ovarian cancer.
• Lynch Regenerative MedicineminorChannel Partner/ Reseller/ Distributor · 1 January 2026Lynch Regenerative Medicine entered into a distribution agreement with Lynch Biologics, a Geistlich North America company, to offer the FDA-approved GEM 21S product in the United States. This expands Lynch's regenerative medicine portfolio.
• StimLabs (FDA 510(k) Collaboration)minorStrategic or Co-development Partner · 1 January 2026StimLabs received FDA 510(k) clearance for DermaForm, a collagen scaffold particulate wound care device developed in collaboration with Geistlich. This regulatory milestone enhances StimLabs' product offerings for treating complex and chronic wounds.
• StrykercoreStrategic or Co-development Partner · 1 March 2025Geistlich Pharma AG announced a strategic partnership with Stryker in March 2025 to co-develop and commercialize next-generation collagen barrier membranes for dental regeneration.
• Bionnovation BiomedicalcoreStrategic or Co-development Partner · 5 April 2024Geistlich signed an agreement to acquire Bionnovation Biomedical in Brazil. The acquisition aims to expand Geistlich's regenerative product portfolio and enhance access to dental treatments in Latin America and emerging markets. Bionnovation brings expertise in biomaterials for regenerative dentistry and operations in multiple countries, selling in over 20 countries.
• StimLabscoreStrategic or Co-development Partner · 1 January 2024StimLabs and Geistlich expanded their partnership to collaborate on a novel wound care product expected to launch in Q2 2026. The partnership builds on their 2024 exclusive national distribution agreement for Derma-Gide, combining Geistlich's scientific development capabilities with StimLabs' commercial expertise in regenerative medicine. The collaboration aims to set new standards in wound care.
• Lynch BiologicscoreStrategic or Co-development Partner · 27 October 2022Geistlich acquired Lynch Biologics, a US-based medical technology firm specializing in regenerative solutions for dentistry. The acquisition focuses on technology that accelerates bone formation and wound healing, enhancing Geistlich's regenerative portfolio and strengthening its market position in the USA.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Straumann: Global leader in dental implants and one of Geistlich's closest strategic comparables. Straumann offers implants, regenerative materials, and digital workflows, directly overlapping with Geistlich's dental bone and soft tissue regeneration portfolio while operating at significantly larger scale.
• Dentsply Sirona: Largest dedicated dental equipment and consumables manufacturer globally. Dentsply Sirona distributes regenerative materials, surgical instruments, and implant systems, competing directly with Geistlich's dental biomaterial offerings through established dental channel relationships.
• Zimmer Biomet: Major orthopedic medical device company with a substantial orthobiologics and bone graft substitute franchise. Directly comparable to Geistlich's Orthoss bone regeneration line and provides a benchmark for orthopedic regenerative product commercialization at scale.
• Medtronic: Global medical device leader with a significant orthobiologics and spine division. Competes with Geistlich's Orthoss and Chondro-Gide lines, with substantially greater resources for R&D and surgeon relationship management across orthopedic and spine indications.
• Integra LifeSciences: Specialty medical device company with regenerative technology, neurosurgery, and orthopedic franchises. Comparable to Geistlich in collagen-based matrix technology and orthobiologics, particularly in the US specialty surgical market.
• Smith+Nephew: Global medical technology company with established orthopedic and advanced wound care divisions. Direct overlap with Geistlich's Orthoss bone substitute portfolio and Derma-Gide wound care platform, with a much larger commercial footprint.
• Coloplast: Global leader in wound care, ostomy, and continence care products. Comparable to Geistlich in advanced wound care, particularly as Geistlich expands its Derma-Gide and DermaForm portfolio into the US chronic wound management market.

Direct peers

• Organogenesis: US-based regenerative medicine company specializing in advanced wound care and surgical biologics. Comparable to Geistlich in its use of collagen-based and biologic scaffold technology, with overlapping advanced wound care positioning alongside Geistlich's Derma-Gide/DermaForm products.

Emerging players

• MiMedx: US-listed regenerative medicine company focused on placental tissue allografts for wound care and surgical recovery. Comparable to Geistlich in regenerative product positioning but competes via an alternative biologic source (placental tissue vs. collagen/xenograft).
• RTI Surgical: Specialty surgical implant company focused on tissue-based and regenerative products for spine, sports medicine, and dental applications. Directly comparable to Geistlich in biologic and tissue-based implant technology, particularly in the Allodyn allograft line overlap.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/implatec
• Facebookfacebook.com/305026376277200
• LinkedInlinkedin.com/company/geistlich-pharma-ag

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Geistlich Pharma